and Supplementary Fig. 1 ), four more cases with a microdeletion (patients 7-10) were identified. In total, ten patients (patients 1-10) had overlapping heterozygous interstitial microdeletions at 19q13. 11-19q13 .12 ( Fig. 1a and Table 1 ). Microdeletions detected by diagnostic microarray were verified by established laboratory protocols and confirmed as de novo where parental testing was possible (Supplementary Table 2 ). The smallest region of overlap extended from 36, 191 ,100-36,229,548 bp (GRCh37/hg19), encompassing two genes curated by the HUGO Gene Nomenclature Committee, ZBTB32 (zinc-finger-and BTB-domain-containing 32) and KMT2B (MLL4) (Fig. 1a) .
Among the remaining 28 cases without a 19q microdeletion, we performed either whole-exome (n = 6) or whole-genome (n = 9) sequencing in 15 cases (Online Methods). We identified heterozygous sequence variants within KMT2B in 6 of the 15 cases (patients 13, 14, 17, 21, 22 and 27) . Sanger sequencing of KMT2B in the other 13 individuals identified one additional mutation-positive case (patient 16). Through national and international collaborations (Online Methods and Supplementary Fig. 1 ), we subsequently ascertained ten additional cases (patients 11, 12, 15, 18, 19, 20, 23, 24, 25 and 26a) . Overall, we identified 17 patients with intragenic heterozygous KMT2B variants (Fig. 1b and Table 1 ). These frameshift insertions (n = 1), frameshift deletions (n = 6), and splice-site (n = 1), stopgain (n = 2) and missense (n = 7) variants were confirmed by Sanger sequencing (Supplementary Tables 2 and 3) . Whole-exome and whole-genome analyses did not identify pathogenic variants in (i) ZBTB32, (ii) known dystonia-associated genes, and (iii) genes with causal roles in other neurodevelopmental disorders. Where possible, mutations in TOR1A (NM_000113.2), THAP1 (NM_018105.2) and GNAL (NM_182978.3) were excluded by diagnostic single-gene testing, next-generation multiple-gene panels and research Sanger sequencing (Supplementary Table 4) .
Parental DNA was available for 23 of the 27 cases, and familial segregation studies verified that the interstitial deletions or intragenic variants had arisen de novo in 20 patients ( Supplementary Fig. 2 and Supplementary Table 2). Three patients had maternally inherited missense variants (patients 22, 26a and 27) . The KMT2B variant identified in patient 26a had occurred de novo in this patient's symptomatic mother (patient 26b) (Supplementary Table 2 ).
Phenotypic characterization of patients with KMT2B variants
We identified 27 patients (age 6-40 years at diagnosis; 14 female and 13 male) with KMT2B variants who presented with clinical symptoms Fig. 3 ). Most patients (21/27) had lower-limb symptoms at disease onset, leading to foot posturing, toe walking and gait disturbance (Fig. 2a) . Four of the 27 patients presented initially with upper-limb symptoms associated with abnormal postures (Fig. 2b,c) and dystonic tremor, leading to reduced dexterity and handwriting difficulties ( Supplementary Fig. 4a,b) . With increasing age, cervical symptoms (torticollis and retrocollis) (Fig. 2d,e) and cranial involvement (facial dystonia, oromandibular involvement with dysarthria/anarthria and difficulties in chewing and swallowing) became prominent features in the majority of patients. In many patients, progressively severe dysphonia was suggestive of laryngeal involvement. None of the patients had airway compromise, and videostroboscopy was not undertaken. Over time, most patients (24/27) developed progressive, generalized dystonia, occurring 2-11 years after initial presentation (Fig. 2f) . The dystonia was persistent in nature, absent in sleep, worsened by voluntary action and associated with overflow muscle activation. Some patients had dystonic tremor. Sudden, brief involuntary muscle jerks, clinically consistent with myoclonus, were evident in two cases (patients 14 and 27). For a few subjects, dystonia was exacerbated when they were systemically unwell. Stepwise deterioration following intercurrent illness was particularly evident in patient 14, and status dystonicus, triggered by a urinary tract infection, was reported in patient 3. Many patients with KMT2B variants had additional clinical findings, including microcephaly, seizures, spasticity and eye movement abnormalities (strabismus, saccade initiation failure and oculomotor apraxia) ( Table 2) . Dysmorphic features and characteristic facial appearance (elongated face and bulbous nasal tip) ( Fig. 2g and Table 2 ) were commonly reported. Developmental delay, intellectual disability, systemic (dermatological, renal and respiratory) features and psychiatric symptoms were also present in some individuals ( Table 7) . Subtle, symmetrical hypointensity of the globus pallidi (with a hypointense streak of bilateral globus pallidus externa) was evident on MR images, known to demonstrate the magnetic resonance phenomenon of susceptibility (T2-weighted, T2*-weighted, susceptibility-weighted and echo-planar imaging b0-diffusion imaging data sets) (Fig. 3) . Mean age at neuroimaging was significantly lower for patients with MR imaging abnormalities (11.7 years) than for those with normal brain scans (19.0 years) (P = 0.0167) (Supplementary Fig. 5a-c) . Single-positron emission tomography using 123 I (DaTSCAN) and [ 18 F]-FDG-PET-CT glucose uptake studies, each undertaken in three patients, were normal ( Supplementary  Fig. 5d and Supplementary Table 7) .
Deep brain stimulation leads to clinical benefit in KMT2B dystonia
Overall, medical therapies were not clinically beneficial. None of the patients had a sustained response to levodopa treatment or other commonly used anti-dystonic agents ( Table 1) . Ten patients had symptomatic treatment with bilateral globus pallidus interna deep brain stimulation (GPi-DBS) ( Table 1 ). All showed clinical benefit, which was particularly striking in some of the younger patients. Patient 6 showed substantial reduction of torticollis and retrocollis, with improvements in motor function and gait. Patient 8 showed a sustained clinical response 6 years after DBS insertion, with improvement of dystonia, which was even more evident after replacement of a faulty right DBS lead. Patient 9 had generalized dystonia and could not walk independently before DBS. Two weeks after DBS insertion, he dramatically regained independent ambulation with marked improvement of dystonic symptoms (Supplementary Video 8) . Patients 17 and 21 were predominantly wheelchair dependent before DBS insertion, but both patients showed restoration of independent walking and improvement of dystonia after DBS (Supplementary Videos 9 and 10). Patient 19 had amelioration of oromandibular symptoms with DBS. Patient 20 had DBS inserted at age 32 years, and, although most benefits were only transient, sustained improvement of foot posture was reported. Patient 23 had significant reduction of dystonic symptoms after DBS insertion. Patient 22, 9 months after DBS insertion (Supplementary Video 11), and patient 25, 4 months after DBS insertion, both showed substantial gains in hand function and independent walking with improvement of dystonia. For five patients, it has been over 3 years since DBS insertion, and all report a sustained reduction in dystonia, with restoration of function and prevention of progressive disability.
KMT2B is constrained for missense and predicted protein-truncating variants
Patients 13, 14, 17 and 21 underwent whole-genome sequencing as part of the National Institute for Health Research (NIHR)-funded BioResource-Rare Diseases project. Enrichment analysis was undertaken in this cohort to determine whether predicted protein-truncating variants (PPTVs) in KMT2B were observed more frequently in patients than would be expected by chance. Given the size and sequence context of KMT2B, 5.73 × 10 −3 de novo KMT2B PPTVs would be expected to occur by chance in the subset of the NIHR BioResource-Rare Diseases cohort with pediatric-onset neurological disease, but three PPTVs were observed. This represents a significant enrichment (P = 3.12 × 10 −8 ). Furthermore, in the Exome Aggregation Consortium (ExAC) database, KMT2B is highly constrained for PPTVs (accessed July 2016) 8 , providing supportive evidence of its potential involvement in disease. The ExAC database reports 712 KMT2B missense variants. Most of these are rare, as expected for a cohort of this size, and the median CADD score 9 for these variants is 22.9. The median CADD score for the missense variants identified in our KMT2B dystonia cohort was significantly higher at 29.1 (P = 0.0001364; Supplementary Table 3) . Given the size and sequence context of KMT2B, 956 missense variants are predicted to occur by chance, suggesting that KMT2B may also be constrained for missense variation (z = 4.06) 8 .
KMT2B variants are predicted to destabilize protein structure
We performed in silico homology modeling studies to generate hypotheses regarding the predicted effects of sequence variants on the structure-function properties of KMT2B (NP_055542.1) (Supplementary Note). On the basis of Pfam domain assignments, KMT2B has a CXXC zinc-finger domain, multiple PHD domains, an F/Y-rich N terminus (FYRN), an F/Y-rich C terminus (FYRC) and a C-terminal SET domain (Fig. 4a) . The modeled variants occurred in residues within the PHD-like, FYRN, SET and FYRC-SET linking domains ( Fig. 4b-d) . Evaluation of a number of variants using MAESTRO 10 and DUET 11 suggests a change in the free energy, with a predicted structure-destabilizing effect (Supplementary Note). A r t i c l e s Variants p.Phe1662Leu and p.Gly1652Asp occur within a PHD-like domain (residues 1574-1688) predicted to facilitate interaction with DNA, protein-protein interaction and recognition of methylated/ unmethylated lysines [12] [13] [14] . Extensive hydrophobic interactions hold the globular structure of this region, which is important for its function 12 . Phe1662 is fully buried at the core, stabilizing the structure of this PHD-like domain, while Gly1652 is partially buried (Fig. 4b,e,f) . Phe1662 is involved in multiple hydrophobic contacts at the core of the PHD domain, and exchange for leucine is predicted to cause loss of contacts at the core (Fig. 4g) . Gly1652 is located on a loop (Fig. 4e) , and substitution to aspartic acid is predicted to alter surface charge, with possible effects on the interaction network in the vicinity, involving a positively charged Arg1635 residue that is part of the α3 helix implicated in DNA binding 12 . Arg1762 and Leu1781 occur in an FYRN domain. FYRN and FYRC regions, particularly common in MLL histone methyltransferases, interact to form a compact structural unit (Fig. 4c,h ) important in maintaining the active structure 15, 16 . Arg1762 forms hydrogen bonds with the backbone carboxyl groups of Arg2463 and Leu2464 in the FYRC domain. Substitution of Arg1762 by cysteine is predicted to abolish these contacts and hence contribute to destabilization of FYRC-FYRN association. Leu1781, at the interface between FYRN and FYRC (Fig. 4h,i) is surface exposed and involved in backbone hydrogen bonds stabilizing the β sheet formed together by the two domains. Substitution to proline (p.Leu1781Pro) is predicted to disrupt the backbone hydrogen bond at this position, as it lacks one hydrogen bond donor and its backbone torsion angles are not compatible with those of a β sheet. This predicts a destabilizing effect on sheet structure, potentially affecting the normal association of FYRN and FYRC domains. Arg2517 resides in the region linking the FYRC and SET domains, known to bind WDR5, an effector required for histone H3 trimethylation 17 , presenting methylated histone H3 substrates to the MLL complex for further methylation 18 . Arg2517 is thought to be involved in a salt bridge interaction with Asp172 of WDR5 (NP_438172.1) (Fig. 4j) , and p.Arg2517Trp is predicted to lead to loss of this interaction. Ile2674, Tyr2688 and Ile2694 all occur in the catalytic methyltransferase SET domain common to histone lysine methyltransferases. Ile2674 is buried in the hydrophobic core, adjacent to the catalytic site (Fig. 4d,k) . Substitution to threonine is predicted to lead to loss of contacts at the core of the domain (owing to the shorter side chain) and also introduces a buried polar group (Fig. 4l) . p.Tyr2688Thr occurs at the core of the SET domain involving extensive hydrophobic interactions and a hydrogen bond interaction with Ser2661 (Fig. 4m) . The frameshift alteration p.Tyr2688Thrfs*50, with insertion of 50 additional residues, is predicted to destabilize the core and affect contacts because of the substitution with a shorter non-aromatic side chain. Ile2694 is involved in the extensive hydrophobic contacts stabilizing the core of this domain. In silico analysis predicts that the frameshift mutation encoding p.Ile2694Serfs*44 will disrupt the domain fold and affect methyltransferase activity.
KMT2B is ubiquitously expressed with reduced expression in KMT2B dystonia
We confirmed widespread KMT2B expression in a variety of control fetal and adult human tissues ( Fig. 5a and Supplementary Fig. 6 ). Moreover, KMT2B is ubiquitously expressed in the brain, with higher expression in the cerebellum than in any other region (Fig. 5b) . We ascertained fibroblasts from all patients consented for research testing (patients 2, 13, 14 and 16, all with microdeletions or PPTVs in KMT2B) and detected a statistically significant decrease in fibroblast KMT2B expression on qRT-PCR when compared to control fibroblasts (Fig. 5c) .
Histone H3K4 methylation is not globally reduced in KMT2B dystonia
To determine the effect of KMT2B variants on methylation of lysine 4 on histone H3 (H3K4 methylation), we assayed trimethylated H3K4 (H3K4me3) and dimethylated H3K4 (H3K4me2). Immunoblotting of histones extracted from fibroblasts obtained from patients 14 and 16 showed no significant reduction in H3K4me3 or H3K4me2 levels relative to control samples ( Fig. 5d and Supplementary Fig. 7a) . A Dictyostelium discoideum model was used to test the effect of SET domain variant p.Ile2647Thr on in vivo histone methyltransferase activity. The SET domain of KMT2B has 56% sequence identity with the Dictyostelium ortholog DdSet1, and Ile2647 is conserved (the corresponding residue in Dictyostelium is Ile1447; XP_636258.1) (Supplementary Fig. 8f ). DdSet1 is the only H3K4 methyltransferase in Dictyostelium, and targeted knockout of DdSet1 (set1 − ) results in loss of all methylation at H3K4 (ref. 19) . We constitutively expressed wildtype DdSet1 and mutant DdSet1, both with N-terminal GFP fusions, in set1 − Dictyostelium cells and compared the resulting levels of H3K4 methylation. Expression of either GFP-fused wild-type DdSet1 or GFPfused mutant DdSet1 in set1 − cells resulted in rescue of H3K4me3 to wild-type levels ( Fig. 5e and Supplementary Fig. 7b,c) .
Altered gene and protein expression in KMT2B dystonia
To determine whether KMT2B dystonia is associated with dysregulation of specific genes and proteins, we investigated (i) gene and protein expression profiles for THAP1 and torsin-1A in cultured patient-derived fibroblasts from patients 2, 13, 14 and 16 and (ii) tyrosine hydroxylase and dopamine 2 receptor (D2R) protein levels in CSF from patients 2 and 16 ( Supplementary Figs. 9 and 10, and Supplementary Note).
We found significantly reduced transcript levels of THAP1 and TOR1A when compared to control fibroblasts (Supplementary Fig. 11a ).
Fibroblast immunoblotting studies showed a statistically significant reduction in THAP1 protein expression in all four patients when compared to control samples (Supplementary Fig. 11b) . A statistically significant reduction in torsin-1A levels was evident in patient 14, although not in the other patients (Supplementary Fig. 11c ). CSF immunoblotting showed significantly reduced levels of D2R and an increase in tyrosine hydroxylase levels (Supplementary Fig. 11d ). 
A r t i c l e s

DISCUSSION
We report 27 individuals with heterozygous variants in the lysine methyltransferase gene KMT2B and define a new genetic movement disorder that, notably, is amenable to treatment with DBS. Using the current classification system 2 , KMT2B dystonia is defined as an inherited autosomal dominant, complex, combined dystonia usually of infantile or childhood onset. In most patients, the dystonia is persistent and progressive in nature. Most individuals develop four-limb dystonia with particularly prominent cervical, laryngeal and oromandibular symptoms. Although the majority of patients seem to follow this disease trajectory, we also report one young case (patient 10, age 7 years) with developmental delay and intermittent toe walking only. Furthermore, we describe atypical cases with mainly oromandibular features (patient 18) or paroxysmal cervical dystonia (patient 26a) and relatively little involvement of the upper or lower limbs. For many patients, KMT2B dystonia is associated with a number of additional clinical features, including other neurological symptoms, intellectual disability, psychiatric comorbidity, dysmorphia, skin lesions and other systemic signs. Given the association with active gene expression, it is conceivable that KMT2B variants could account for these additional disease features. For patients 1-10, other genes within the 19q microdeletion may also contribute to aspects of their http://www.braineac.org/). Expression levels are based on exon array experiments as previously described and are plotted on a log 2 scale (y axis) 40 . KMT2B is ubiquitously expressed across all ten brain regions analyzed, with expression highest in the cerebellum. PUTM, putamen; FCTX, frontal cortex; TCTX, temporal cortex; OCTX, occipital cortex; HIPP, hippocampus; SNIG, substantia nigra; MEDU, medulla (specifically inferior olivary nucleus); WHMT, intralobular white matter; THAL, thalamus; CRBL, cerebellar cortex. n indicates the number of brain samples analyzed to generate the results for each brain region. Ranges extend from the box to 1.5 times the interquartile range. clinical phenotype 20 . KMT2B variants, therefore, cause a complex dystonia, and affected patients should have close surveillance of development during childhood, regular neurology assessments, routine dermatological review and formal neuropsychiatric testing. In KMT2B dystonia, the majority of patients had a characteristic pattern on MR imaging, with subtle, low pallidal signal on T2*-, diffusion-and susceptibility-weighted sequences, particularly affecting the lateral aspect of the globus pallidus externa (Fig. 3) . Genotype did not appear to influence MR findings. However, those with abnormal imaging had scans undertaken at a significantly younger age than those with normal imaging. MR abnormalities could be an age-dependent phenomenon, perhaps becoming less apparent with increasing age, as evident in serial imaging from patient 22 (Supplementary Fig. 5b,c and Supplementary Table 7 ). The overall significance of these neuroradiological abnormalities remains unclear. Such findings are reminiscent of, but different from, those reported in neurodegeneration with brain iron accumulation (NBIA) syndromes 21, 22 . Similar nonspecific features of T2*-weighted hypointensity are increasingly being recognized in other neurological conditions, including Huntington disease, TUBB4A-related disorders, GM1 gangliosidosis, α-fucosidosis and mitochondriocytopathies.
KMT2B variants were identified in 13 of 34 (38%) individuals with a relatively homogenous phenotype of early-onset progressive dystonia. For externally screened cohorts, detection rates varied from 1.3-30% according to the phenotypic focus of the cohort (Supplementary Fig. 1 ). For cases where KMT2B mutations were not detected, it is likely that another etiology accounts for their symptoms. However, it is possible that KMT2B mutations may have been missed, as (i) single-/multiple-exon KMT2B deletions and duplications may not be detected on microarray, Sanger sequencing and whole-exome or whole-genome sequencing and (ii) promoter mutations and intronic KMT2B variants may not have been identified by whole-exome and Sanger sequencing.
The majority of individuals with KMT2B variants (patients 1-20) had either heterozygous interstitial microdeletions leading to KMT2B haploinsufficiency or variants predicted to cause protein truncation, protein elongation, splicing defects or nonsense-mediated mRNA decay. The seven remaining patients (patients 21-27) had nonsynonymous variants of KMT2B. Although a degree of caution must be exercised for missense variants, those identified in our cohort are (i) described in patients with a compatible phenotype, (ii) predicted to affect conserved residues within key protein domains for five of seven cases (Supplementary Figs. 8 and 12 ) and (iii) predicted by in silico tools to be deleterious with a destabilizing effect on protein structure (Supplementary Table 3) . Initial disease presentation was significantly later in those with missense variants ( Supplementary  Fig. 3) , although genotype did not seem to influence the subsequent rate of symptom evolution, disease severity or DBS response.
For the majority of patients, KMT2B variants were confirmed as de novo where parental testing could be undertaken. In our cohort, three patients had missense changes that were maternally inherited (patients 22, 26a and 27). The possibility of imprinting at the disease locus was considered but deemed unlikely, given that (i) de novo microdeletions in patients 2 and 10 occurred on the paternally inherited alleles and (ii) there is biallelic expression of KMT2B SNPs in human tissues, including brain (Supplementary Fig. 13) . Notably, whole-exome sequence analysis undertaken in patients 22, 26a and 27 did not identify other rare or de novo variants to account for disease. Interestingly, patient 26a inherited p.Arg2517Trp from his symptomatic mother (patient 26b) in whom the change occurred de novo (Supplementary Fig. 2) . The mother was more mildly affected, with onset of symptoms in early adulthood, reporting gait abnormalities, progressive inability to run and periodic paroxysmal upper-limb and neck dystonia. Both had similar facial appearances to others in the cohort (Fig. 2g) . In contrast, the mothers of patients 22 and 27 were clinically examined and neither had evidence of a motor phenotype, intellectual disability, other neurological features, neuropsychiatric symptoms, facial dysmorphia, skin lesions or other systemic signs. The identification of both symptomatic and asymptomatic carriers suggests either 'apparent' incomplete penetrance, due to parental mosaicism, or true incomplete disease penetrance, a phenomenon commonly reported in other autosomal dominant genetic dystonias 23, 24 . Other genetic, epigenetic and environmental modifiers may also influence disease penetrance and phenotypic presentation in KMT2B dystonia.
KMT2B encodes a ubiquitously expressed lysine methyltransferase specifically involved in H3K4 methylation 25, 26 , an important epigenetic modification associated with active transcription. H3K4me3 is enriched at promoters, marking the transcriptional start sites of actively transcribed genes, whereas H3K4me1 is associated with active enhancer sequences 27 . H3K4me2 is less specifically localized but may be enriched at transcription factor binding sites 28 . Members of the SET/MLL protein family, including KMT2B, are responsible for the generation of H3K4me1, H3K4me2 and H3K4me3, which are essential for gene activation in normal development 29 . Using patientderived fibroblasts and a Dictyostelium model, we demonstrated that KMT2B variants are not associated with widespread alterations in the overall levels of H3K4 methylation. This is not surprising, given that haploinsufficiency for other MLL family members has not been convincingly shown to affect global H3K4 methylation levels. The fundamental physiological role of MLL proteins is affirmed by the observation that loss-of-function heterozygous mutations in MLLencoding genes are reported in a number of human developmental disorders 30 , namely Wiedemann Steiner (KMT2A, MLL1) 31 , Kleefstralike (KMT2C, MLL3) 32 and Kabuki (KMT2D, MLL2) 33 syndromes and, most recently, SETD1A-related disease (KMT2F) 34 . Although the physiological functions of MLL proteins are yet to be fully characterized, the observation that mutations in different MLL genes cause phenotypically distinct syndromes (Supplementary Table 8) suggests that each MLL protein has a unique role, regulating the expression of a specific set of genes 35, 36 .
Among the previously reported disorders associated with MLL genes, dystonia appears to be fairly specific to KMT2B-related disease and is not commonly described in other MLL syndromes (Supplementary Table 8) , providing further evidence that different MLL proteins mediate the activation and transcription of a specific set of genes, with temporal and cellular context 37 . To determine the downstream effects of KMT2B mutations, we investigated the expression profiles of specific genes and proteins implicated in the pathogenesis of dystonia using patient-derived fibroblasts and CSF (Supplementary Figs. 9-11 and Supplementary Note). We detected a statistically significant reduction in THAP1 and TOR1A gene expression and decreased THAP1 protein expression in fibroblasts. CSF immunoblotting studies showed reduction in D2R protein and increase in tyrosine hydroxylase levels in two patients with KMT2B dystonia when compared to control CSF samples. The mechanisms causing such alterations in KMT2B dystonia remain to be elucidated. While H3K4 methylation is clearly associated with the process of active transcription, several studies have shown that H3K4 methylation is required, not for absolute transcriptional output, but rather for transcription stability or consistency 38, 39 , so the effects of KMT2B haploinsufficiency could conceivably operate via an intermediary sensitive to stochastic fluctuations. It is highly likely that dysregulation ofother genes and proteins is also involved in the disease pathophysiology of KMT2B dystonia. Further studies will determine whether the expression profiles of other genes and proteins are affected in KMT2B dystonia and contributory to the phenotype.
In conclusion, we report KMT2B variants in 27 patients with a clinically recognizable form of dystonia. Thus far, the underlying genetic etiology is only resolved in a minority of childhood-onset cases of dystonia, which precludes confirmatory diagnosis, accurate disease prognostication and selection of appropriate treatment strategies. We have shown that many patients with KMT2B dystonia have significant, sustained clinical improvement with DBS. Referral for DBS assessment should therefore be considered for this group. Identification of additional cases will allow further characterization of the full phenotypic disease spectrum. Our report highlights mutations in KMT2B as a new and important cause of complex early-onset dystonia, emphasizing the crucial role of KMT2B in the control of voluntary movement. 
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINE METHODS
Case ascertainment. Case ascertainment is summarized in
Whole-exome and whole-genome sequencing. Whole-exome and wholegenome sequencing was undertaken using center-specific protocols (see below). Reads were aligned to the GRCh37/hg19 reference genome. Detailed variant analysis was performed for single-nucleotide variants (SNVs) and small indels that (i) passed standard local quality filters, (ii) were predicted to alter protein sequence at conserved residues, (iii) were predicted to be deleterious by bioinformatics tools (including SIFT, PolyPhen-2, LRT, MutationTaster and CADD), and (iv) had an allele frequency <0.01 in the 1000 Genomes Project 41 , NHLBI GO Exome Sequencing Project, UK10K 42 and ExAC 8 databases and internal-control exomes and genomes. Data analysis was initially undertaken for known disease-causing genes before analysis for autosomal recessive and dominant inheritance models.
NIHR BioResource-Rare Diseases Study. Whole-genome sequencing was undertaken using the Illumina TruSeq DNA PCR-Free Sample Preparation kit on the Illumina HiSeq 2500 platform, generating minimum coverage of 15× for ~95% of the genome and average coverage of ~30×. Reads were aligned using the Isaac aligner (version 01.14, Illumina) 43 . SNVs and indels were identified using the Isaac variant caller (version 2.0.17).
Wellcome Trust UK10K Rare Diseases project. DNA samples were captured using the Agilent SureSelect Target Enrichment V5 (Agilent Technologies) pulldown array. Whole-exome sequencing was performed on the Illumina HiSeq 2000 platform. Reads were aligned using the Burrows-Wheeler Alignment tool. SNVs and indels were identified with SAMtools 44, 45 . Variants were identified for each sample using the Genome Analysis Toolkit (GATK) UnifiedGenotyper 46 and were annotated with vcf-annotate 47 and Ensembl Variant Effect Predictor v73 (VEP) 48 .
National Institutes of Health, Bethesda. Exome sequencing was completed using the TruSeq V2 exome capture kit. Data were aligned and processed as previously decribed [49] [50] [51] .
Institute of Human Genetics, Erlangen. Exome sequencing was performed on an Illumina HiSeq 2500 platform with 125-bp paired-end sequencing using SureSelect V5 capture reagents (Agilent Technologies).
Radboud University Medical Center, Nijmegen. Exome sequencing was undertaken using the Agilent SureSelect XT Human All Exon 50 Mb kit, with sequencing on the SOLiD 5500XL platform, producing an average sequence depth of 91× and average coverage of at least 20× for 89% of targets. For variant calling and annotation, a custom in-house diagnostic pipeline was deployed 52 .
UCL-Institute of Neurology, London. Exome sequencing was performed using Illumina Nextera Rapid Capture. Indexed and pooled libraries were sequenced on an Illumina HiSeq 3000 instrument (100-bp paired-end reads). Reads were aligned with Novoalign. Duplicate read removal, format conversion and indexing were performed with Picard. GATK was used to recalibrate base quality scores, to perform local realignments around possible indels, and to call (HaplotypeCaller) and filter (VQSR) variants 46 . Annotated variant files were generated using ANNOVAR 53 .
Deciphering Developmental Disorders study. Exome sequencing of family trios was performed using Agilent SureSelect Exome bait design (Agilent Human All Exon V3 Plus with custom ELID C0338371 and Agilent Human All Exon V5 Plus with custom ELID C0338371) on an Illumina HiSeq instrument at the Wellcome Trust Sanger Institute as previously described 54, 55 . Data are currently available on 4,295 trios which were interrogated via a DDD complementary research proposal (CAP#120).
Sanger sequencing for variant validation and gene screening. Direct sequencing was undertaken to (i) screen the entire coding region of KMT2B for 13 cases from the GOS-ICH cohort (Supplementary Table 1 ), (ii) confirm variants identified in next-generation sequencing, and (iii) establish familial segregation (Supplementary Fig. 2) . Additionally, cDNA from fibroblasts and patient-derived dopaminergic neurons was sequenced for a common SNP in exon 30 (rs231591). Primer pairs for all 37 coding exons and exonintron boundaries of KMT2B (Ensembl ENSG00000272333, transcript ENST00000420124) were designed with Primer3 (Supplementary Table 9 ) 56, 57 . PCR conditions can be provided upon request. PCR products were cleaned up (MicroCLEAN, Web Scientific) and sequenced using the BigDye Terminator Cycle Sequencing System (Applied Biosystems). Sequencing reactions were run on an ABI PRISM 3730 DNA Analyzer (Applied Biosystems) and analyzed using Chromas.
Enrichment analysis. The number of de novo PPTVs in KMT2B expected to be seen by chance in a subset of the NIHR BioResource-Rare Diseases cohort with pediatric-onset neurological disease (n = 272) was calculated using published gene-specific mutation rates 58 and scaled to account for frameshift, nonsense and essential splice-site variants 58 . To assess significance, the expected number of de novo PPTVs was compared to the observed number, assuming a Poisson distribution.
Cerebrospinal fluid neurotransmitter analysis. CSF was collected by lumbar puncture and diagnostically analyzed for neurotransmitter monoamine metabolites in specialist laboratories (London, Barcelona, Sydney and Jerusalem) by high-performance liquid chromatography 59, 60 .
Comparative modeling. In silico homology modeling was used to predict the putative effects of KMT2B variants. The Pfam database 61 was used to assign known domains to the full-length sequence of KMT2B. Evolutionary conservation of residues in the sequence was quantified using the Consurf server 62 , on the basis of alignment with a set of homologous sequences that had 35-95% sequence identity with KMT2B. HHpred 63 was used to identify proteins or domains with known structures that had sequence and structural features similar to those of KMT2B. Selected templates had more than 99% probability (based on HHpred alignment score) of being related structurally to specific domain segments of KMT2B. MODELLER 64 was employed for different regions of KMT2B, and HHpred alignments were used to dictate residue equivalences with the template. For each domain, 150 models were generated with the MODELLER loop optimization protocol and the best model was selected on the basis of the normalized DOPE score 65 . The effect of a point substitution on the stability of the domain structure was evaluated using DUET 11 and MAESTRO 10 . Visualization, analysis of amino acid interactions and generation of mutant models were performed with UCSF Chimera 66 .
H3K4 methylation. Histones were extracted from fibroblasts using a modified version of a published protocol 67 . Cells were lysed by rotating at 4 °C in (patients 2 and 16) and four sex-and age-matched controls (patients with no history of movement disorder on no medication). Immunoblotting was carried out as described above. For the detection of tyrosine hydroxylase and D2R, membranes were incubated with polyclonal rabbit antibody against tyrosine hydroxylase (Millipore, AB152; 1:1,000 dilution) and polyclonal rabbit antibody against D2R (Millipore, AB5084P; 1:1,000 dilution) followed by incubation for 2 h with HRP-conjugated goat anti-rabbit IgG antibody (Cell Signaling Technology, 7074; 1:3,000 dilution). As an internal control for loading, we used monoclonal mouse antibody against transferrin (Santa Cruz Biotechnology, E-8; 1:1,000 dilution) followed by HRP-conjugated horse antimouse IgG antibody (Cell Signaling Technology, 7076; 1:3,000 dilution).
Statistics. The statistical analyses for the histone methylation assays were conducted using GraphPad Prism v7.01 and for the analyses of the fibroblast cell lines and CSF immunoblotting were conducted using GraphPad v5. The final data are represented as means with error bars showing the standard deviation. For multiple comparisons, one-way ANOVA was performed, whereas for dual comparisons unpaired two-tailed Student's t tests were employed. P < 0.05 was considered to be significant: *P < 0.05, **P < 0.01, ***P < 0.001. The F test was used to compare the variances between the groups in dual comparisons.
We assume that technical replicates of immunoblot assays using the same cell lines will be normally distributed. For the fibroblast histone methylation assay, the Brown-Forsythe test was used to check differences in variance between the groups compared and no significant differences was found in standard deviations (H3K4me3, P = 0.7567 (F = 0.2877, DFn = 2, DFd = 9); H3K4me2, P = 0.8446 (F = 0.1721, DFn = 2, DFd = 9)). For the remaining experiments, data distribution was not tested but was assumed to be normal. Blinding was not applied for data collection and analysis.
Data availability. Chromosomal microarray data. Microarray data for patient 1 (326759), patient 2 (326749), patient 3 (326748), patient 4 (326751), patient 5 (326750), patient 6 (326752), patient 7 (285035) and patient 8 (280902) have been deposited in DECIPHER. The data from patient 1 (326759) and patient 8 (280902) are publically available. The remaining patients did not consent for their data to be publicly released.
NIHR BioResource-Rare Diseases Study. Whole-genome sequencing data have been deposited in the NIHR BioResource Rare Diseases BRIDGE consortium sequencing projects (short name, NIHR-BR-RD). The data are available in the European Genome-phenome Archive (EGA) under accession EGAS00001001012, with data set title SPEED childhood dystonia KMT2B data set (EGAD00001002730). Data have been deposited for patient 1 (EGAR00001314765), patient 13 (EGAR00001320121), patient 14 (EGAR00001314777), patient 17 (EGAR00001314751) and patient 21 (EGAR00001314767).
UK10K Project. UK10K whole-exome sequencing data have been deposited in EGA under the name UK10K_RARE_FIND with accession EGAS00001000128. The data set is entitled UK10K_RARE_FIND REL-2013-10-31 variant calling (EGAD00001000750). Data have been deposited for patients 22 (UK10K_FIND5536224) and 27 (UK10K_FIND5536279).
Deciphering Developmental Disorders study. Exome sequencing data are accessible via EGA under accession EGAS00001000775.
National Institutes of Health, Bethesda; Institute of Human Genetics, Erlangen; Radboud University Medical Center, Nijmegen; UCL-Institute of Neurology, London. Whole-exome sequencing data have not been deposited because participating patients have not consented for the data to be publicly released.
Source data for Supplementary Figure 11 is available online.
